SEARCH

SEARCH BY CITATION

References

  • Barker EL, Blakely RD (1996). Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 50: 957965.
  • Barker EL, Kimmel HL, Blakely RD (1994). Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol 46: 799807.
  • Beique JC, Lavoie N, de Montigny C, Debonnel G (1998). Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 349: 129132.
  • Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137151.
  • Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK et al. (1991). Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 6670.
  • Bruss M, Porzgen P, Bryan-Lluka LJ, Bönisch H (1997). The rat norepinephrine transporter: molecular cloning from PC12 cells and functional expression. Brain Res Mol Brain Res 52: 257262.
  • Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871880.
  • Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C et al. (2006). Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther 317: 147152.
  • Cheng Y-C, Prusoff WH (1973). Relationship between the inhibition constant (KI) and the concentation of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Feuerstein TJ (2007). Presynaptic receptors for dopamine, histamine and serotonin. Handb Exp Pharmacol 2008: 289338.
  • Feuerstein TJ, Limberger N (1999). Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn Schmiedebergs Arch Pharmacol 359: 345359.
  • Feuerstein TJ, Sauermann W (2005). What is the opposite of a receptor reserve? Int J Pharmacol 1: 195202.
  • Feuerstein TJ, Hertting G, Lupp A, Neufang B (1986). False labelling of dopaminergic terminals in the rabbit caudate nucleus: uptake and release of [3H]-5-hydroxytryptamine. Br J Pharmacol 88: 677684.
  • Frazer A (2001). Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62 (Suppl. 12): 1623.
  • Gardner MJ, Altman DG (1986). Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 292: 746750.
  • Gehlert DR, Schober DA, Gackenheimer SL (1995). Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 64: 27922800.
  • Göthert M, Schlicker E (1997). Regulation of 5-HT release in the CNS by presynaptic 5-HT autoreceptors and by 5-HT heteroreceptors. In: Baumgarten HG, Göthert M (eds). Serotonergic Neurons and 5-HT Receptors in the CNS. Springer: Berlin, Heidelberg and New York, pp. 307350.
  • Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10: 2344.
  • Harms HH (1983). The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res 275: 99104.
  • Hyttel J (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 (Suppl. 1): 1926.
  • Jeannotte AM, Sidhu A (2008). Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons. J Neurochem 105: 16681682.
  • Kasamo K, Blier P, de Montigny C (1996). Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 277: 278286.
  • Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley M (1980). High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. Science 210: 11331135.
  • Lieb K, Fiebich BL, Herpfer I, Mantovani M, Löffler M, Feuerstein TJ (2005). No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharmacol 15: 641646.
  • Löffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R et al. (2006). Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain Res Bull 68: 361373.
  • Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265275.
  • Lupp A, Bär KI, Lücking CH, Feuerstein TJ (1992). Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals. Psychopharmacology 106: 118126.
  • Mann CD, Hrdina PD (1992). Sodium dependence of [3H]paroxetine binding and 5-[3H]hydroxytryptamine uptake in rat diencephalon. J Neurochem 59: 18561861.
  • Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283: 13051322.
  • Pacholczyk T, Blakely RD, Amara SG (1991). Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350354.
  • Plenge P, Mellerup ET (1991). [3H]citalopram binding to brain and platelet membranes of human and rat. J Neurochem 56: 248252.
  • Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS et al. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90: 25422546.
  • Richelson E, Pfenning M (1984). Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277286.
  • Ruhé HG, Mason NS, Schene AH (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12: 331359.
  • Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19: 467489.
  • Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10: 732747.
  • Steffens M, Feuerstein TJ (2004). Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex – involvement of Na(+)/K(+)-ATPase. Neurochem Int 44: 529538.
  • Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ (2004). Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55: 320322.
  • Wheeler DD, Edwards AM, Ondo JG (1993). Dopamine uptake in five structures of the brain: comparison of rate, sodium dependence and sensitivity to cocaine. Neuropharmacol 32: 501508.
  • Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993). LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8: 2333.
  • Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al. (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818829.
  • Wood MD (1987). Examination of the relationship between the uptake site for 5-hydroxytryptamine and the high affinity binding site for [3H]imipramine. II. The role of sodium ions. Neuropharmacology 26: 10811085.
  • Zhou J (2004). Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29: 12351244.